ICC panel rules in flu drug dispute
North Carolina-based Biocryst Pharmaceuticals has reported a favourable ICC award terminating its agreement with an Australian-owned company for licensing of the world’s first intravenous flu treatment.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access